Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company specializing in rare and ultrarare diseases, has announced the grant of 62,555 restricted stock units to 16 newly hired non-executive officers. The grants were approved by the company's compensation committee and issued under the Ultragenyx Employment Inducement Plan on September 16, 2024. This action complies with Nasdaq Listing Rule 5635(c)(4), serving as an inducement for new employees joining Ultragenyx. The restricted stock units have a four-year vesting schedule, with 25% of the shares vesting annually, contingent on continuous employment.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), un'azienda biofarmaceutica specializzata in malattie rare e ultrarare, ha annunciato l'assegnazione di 62.555 unità di azioni a restrizione a 16 nuovi dirigenti non esecutivi. Le assegnazioni sono state approvate dal comitato compensativo dell'azienda e rilasciate nell'ambito del Piano di Induzione all'Occupazione di Ultragenyx il 16 settembre 2024. Questa azione è conforme alla Regola di Quotazione di Nasdaq 5635(c)(4), servendo come incentivo per i nuovi dipendenti che si uniscono a Ultragenyx. Le unità di azioni a restrizione hanno un programma di maturazione di quattro anni, con il 25% delle azioni che matura annualmente, soggetto a continuo impiego.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), una compañía biofarmacéutica especializada en enfermedades raras y ultrararas, ha anunciado la concesión de 62,555 unidades de acciones restringidas a 16 nuevos funcionarios no ejecutivos. Las concesiones fueron aprobadas por el comité de compensación de la empresa y emitidas bajo el Plan de Inducción al Empleo de Ultragenyx el 16 de septiembre de 2024. Esta acción cumple con la Regla de Cotización de Nasdaq 5635(c)(4), sirviendo como incentivo para los nuevos empleados que se unen a Ultragenyx. Las unidades de acciones restringidas tienen un cronograma de adquisición de cuatro años, con el 25% de las acciones adquiriéndose anualmente, condicionado a la continuidad del empleo.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), 희귀 및 초희귀 질환을 전문으로 하는 생물 제약 회사는 62,555 제한 주식 단위를 16명의 새로운 비임원 직원에게 부여했다고 발표했습니다. 이 부여는 회사의 보상 위원회에 의해 승인되었으며, 2024년 9월 16일 Ultragenyx 고용 유도 계획에 따라 발급되었습니다. 이 조치는 Nasdaq 상장 규정 5635(c)(4)과 일치하며, Ultragenyx에 합류하는 새로운 직원에 대한 유도책으로 기능합니다. 제한 주식 단위는 4년의 취득 일정을 가지며, 고용이 계속되는 조건으로 연간 25%의 주식이 취득됩니다.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), une entreprise biopharmaceutique spécialisée dans les maladies rares et ultraraires, a annoncé l'octroi de 62 555 unités d'actions restreintes à 16 nouveaux dirigeants non exécutifs. Les octrois ont été approuvés par le comité de rémunération de l’entreprise et émis dans le cadre du Plan d'Incitation à l'Emploi d'Ultragenyx le 16 septembre 2024. Cette action est conforme à la Règle de Cotation Nasdaq 5635(c)(4), servant d'incitation pour les nouveaux employés rejoignant Ultragenyx. Les unités d'actions restreintes ont un calendrier d'acquisition de quatre ans, avec 25 % des actions acquises chaque année, sous réserve de l'emploi continu.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), ein biopharmazeutisches Unternehmen, das sich auf seltene und ultrarare Krankheiten spezialisiert hat, hat die Gewährung von 62.555 eingeschränkten Aktieneinheiten an 16 neu eingestellte nicht-executive Mitarbeiter bekannt gegeben. Die Gewährungen wurden vom Vergütungsausschuss des Unternehmens genehmigt und im Rahmen des Ultragenyx Employment Inducement Plans am 16. September 2024 ausgegeben. Diese Maßnahme entspricht der Nasdaq-Listing-Regel 5635(c)(4) und dient als Anreiz für neue Mitarbeiter, die zu Ultragenyx stoßen. Die eingeschränkten Aktieneinheiten haben einen Vesting-Zeitplan von vier Jahren, wobei 25 % der Anteile jährlich vesten, vorausgesetzt, dass das Arbeitsverhältnis ununterbrochen besteht.
- Attraction of new talent with 16 non-executive officers hired
- Implementation of employee retention strategy through restricted stock units
- Potential dilution of existing shareholders' stock value due to new stock unit grants
NOVATO, Calif., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare diseases, today reported the grant of 62,555 restricted stock units of the company’s common stock to 16 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company’s board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of September 16, 2024, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).
The restricted stock units vest over four years, with
About Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultrarare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.
Contact Ultragenyx
Investors & Media
Joshua Higa
(415) 475-6370
FAQ
How many restricted stock units did Ultragenyx (RARE) grant to new employees?
What is the vesting schedule for the restricted stock units granted by Ultragenyx (RARE)?
When were the restricted stock units granted by Ultragenyx (RARE)?
Under which plan were the Ultragenyx (RARE) stock units granted?
